News

The transthyretin amyloidosis market size is projected to grow significantly during the forecast period (2023–2032) owing to the currently approved drugs, along…

When: Saturday, October 21st, 2023 9:00 am - 2:00 pm Where: Huntsman Cancer Hospital Salt Lake City, Utah In-Person and Virtual Registration Options Available…

On behalf of the Organizing Committee, it is our great pleasure to host the 3rd Utah Amyloidosis Symposium in Salt Lake City, Utah. The 2023 symposium will be held…

When: Sunday, October 15, 2023 | 8:00am-3:00pm Where: Hale Cafe Atrium Brigham & Women's Hospital 60 Fenwood Road 1st Floor Boston, MA 02115 Guests:…

When: Saturday, September 30, 2023 | 9:00am-3:00pm Where: UNC Medical Center Sanofi Conference Room, First Floor 101 Manning Drive Chapel Hill, NC 27514 Guests:…

This Meeting Is for AL Amyloidosis Only When: Saturday, September 9, 2023 | 9:00 am - 2:00 pm Registration: 8:00 am - 9:00 am Meeting: 9:00 - 2:00 pm Lunch: 12:00…

The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy…

Date & Time Saturday, July 15, 2023 12:00 PM ET Description Please join ASG on Saturday, July 15th from 12:00 pm - 3:00 pm ET for the next webinar on ATTRv and…

July 11, 2023 | Cardiovascular Business For years, cardiac amyloidosis was a rare and often fatal disease that had no treatment, so it was not front and center in…

As part of their continued dedication to raising awareness about hATTR amyloidosis and the impact the disease has on those affected, Alnylam Pharmaceuticals is…